There are two Moderna boosters that have been announced, the mRNA-1273.211 and mRNA-1273.214, ones. The .211 candidate is based on the Beta variant spike proteins the trial of which has already been completed, whereas the trial of the .214 candidate that is based on Omicron mutations is expected to complete by or in early June 2022.
Moderna has multiple bivalent booster candidates that have been evaluated to date, which include mRNA-1273.211 (9 spike protein mutations, based on the Beta variant), and mRNA-1273.214 (32 spike protein mutations, based on the Omicron variant). mRNA-1273.211 includes four mutations and mRNA-1273.214 includes 32 mutations present in the Omicron variant of concern.
[…]
A booster dose of mRNA-1273.211 demonstrated superiority against the ancestral SARS-CoV-2 and the Beta, Delta and Omicron variants one month after the booster dose and superiority against the ancestral SARS-CoV-2, Beta and Omicron 6 months compared to the booster dose of mRNA-1273. There was a 2.20-fold (95% CI: 1.74, 2.79) and 2.15-fold (95% CI: 1.66, 2.78) increase in the neutralizing antibody titers against Omicron with the mRNA-1273.211 booster dose compared to the mRNA-1273 booster dose at 1 month and 6 months, respectively.
Some guy got 90 doses of the vaccine so he could sell the "vaccinated" status: https://www.theguardian.com/world/2022/apr/03/german-man-sus... , I wonder if he'll be a case study of what overdosing does (although a sample of one is probably not useful).
9 comments
[ 3.2 ms ] story [ 33.9 ms ] threadFrom https://investors.modernatx.com/news/news-details/2022/Moder... :
I'm not going to give this click bait a page view. What's the deal with Nature these days?